The study concluded that the GLP-2 analog was effective at reducing the volume and numbers of days of parenteral support needed for patients with SBS with intestinal failure [52]. This evidence concerns the gene GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.